Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Ryan Mak who wrote (85371)	2/29/2000 11:59:00 AM
From: Northern Cougar	Read Replies (1) \| Respond to of 120523

Ryan Our CLRS is in the BSB zone OJ must be having lunch celebrating.. EFCX gonna try again here.. @21 1/4 :) N.C.

To: Ryan Mak who wrote (85371)	2/29/2000 12:01:00 PM
From: Susan G	Read Replies (2) \| Respond to of 120523

Ryan - I thought glgc earnings were Thursday - but Yahoo says 3/2. I'll check on it. Gene Logic says completes gene expression survey GAITHERSBURG, Md., Feb 29 (Reuters) - Genomics biotech company Gene Logic Inc. (NasdaqNM:GLGC - news) said on Tuesday it has completed a human gene expression survey of normal human tissue samples of 40 major organs that it aims to sell to drug makers. Gene expression measures the degree to which genes in a cell are switched on or off, or regulated, the company said. The combination of the sequences of the human genes and the knowledge of the genes' activity is used by the company's drug and biotechnology customers to speed up their drug discovery and development efforts. Gene Logic sells its gene expression database products to pharmaceutical, healthcare and life sciences companies. The company currently has 1500 complete tissue profiles, and by the end of 2003, the databases are expected to contain complete profiles on 30,000 tissue samples. These databases contain gene expression profiles of many human diseases. The information can be used for many aspects of drug discovery and development, including target discovery, molecular profiling of drugs, design of clinical trials and ultimately, disease management for individual patients, the company said. Shares of Gene Logic closed at 106-1/2 on Monday, off a 52-week high of 131-3/8, up from a low of 3-3/8.